BRPI1007706A2 - anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo - Google Patents

anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo

Info

Publication number
BRPI1007706A2
BRPI1007706A2 BRPI1007706-5A BRPI1007706A BRPI1007706A2 BR PI1007706 A2 BRPI1007706 A2 BR PI1007706A2 BR PI1007706 A BRPI1007706 A BR PI1007706A BR PI1007706 A2 BRPI1007706 A2 BR PI1007706A2
Authority
BR
Brazil
Prior art keywords
individual
reducing
antibody
inhibiting
egfl7 antibody
Prior art date
Application number
BRPI1007706-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Ye Weilan
Fredrickson Jill
Dennis Mark
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BRPI1007706A2 publication Critical patent/BRPI1007706A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
BRPI1007706-5A 2009-05-08 2010-05-07 anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo BRPI1007706A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17681709P 2009-05-08 2009-05-08
US61/176,817 2009-05-08
PCT/US2010/034097 WO2010129904A1 (en) 2009-05-08 2010-05-07 Humanized anti-egfl7 antibodies and methods using same

Publications (1)

Publication Number Publication Date
BRPI1007706A2 true BRPI1007706A2 (pt) 2019-04-02

Family

ID=42333507

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007706-5A BRPI1007706A2 (pt) 2009-05-08 2010-05-07 anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo

Country Status (24)

Country Link
US (8) US8404811B2 (enExample)
EP (1) EP2427493A1 (enExample)
JP (2) JP5383905B2 (enExample)
KR (1) KR20120005021A (enExample)
CN (3) CN103772500A (enExample)
AR (1) AR076662A1 (enExample)
AU (1) AU2010245739B2 (enExample)
BR (1) BRPI1007706A2 (enExample)
CA (2) CA2760246A1 (enExample)
CL (1) CL2011002784A1 (enExample)
CO (1) CO6450619A2 (enExample)
CR (1) CR20110576A (enExample)
EC (1) ECSP11011430A (enExample)
IL (1) IL216115A0 (enExample)
MA (1) MA33551B1 (enExample)
MX (1) MX2011010570A (enExample)
NZ (1) NZ595641A (enExample)
PE (1) PE20120902A1 (enExample)
RU (1) RU2011149798A (enExample)
SG (1) SG175891A1 (enExample)
TW (2) TW201422237A (enExample)
UA (1) UA105386C2 (enExample)
WO (1) WO2010129904A1 (enExample)
ZA (1) ZA201207484B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4063769B2 (ja) * 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
HUE028121T2 (en) * 2009-06-12 2016-11-28 Cynapsus Therapeutics Inc Sublingual apomorphine
KR102161392B1 (ko) 2010-12-16 2020-10-05 선오비온 파마슈티컬스 인코포레이티드 설하 필름
WO2012106473A2 (en) * 2011-02-02 2012-08-09 Genentech, Inc. Dosing for treatment with anti-egfl7 antibodies
WO2013061112A1 (en) 2011-10-24 2013-05-02 Centre National De La Recherche Scientifique Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium
US9789213B2 (en) * 2012-03-27 2017-10-17 London Health Sciences Centre Research Inc. EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
CN109456400A (zh) 2012-07-23 2019-03-12 西兰制药公司 胰高血糖素类似物
ES2829597T3 (es) * 2013-02-15 2021-06-01 Perseus Proteomics Inc Anticuerpo humanizado anti-CDH3, conjugado de fármaco del mismo y utilización del mismo
AU2013201383B2 (en) 2013-03-01 2015-07-02 Royal Melbourne Institute Of Technology Atomisation apparatus using surface acoustic wave generaton
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AP2016009212A0 (en) 2013-10-17 2016-05-31 Zealand Pharma As Acylated glucagon analogues
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
KR102538348B1 (ko) 2015-09-17 2023-05-31 삼성전자 주식회사 전자 장치 및 전자 장치의 동작 제어 방법
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3615075A4 (en) 2017-04-24 2021-01-20 Ohio State Innovation Foundation RECOMBINANT EGFL7, ANTI-EGFL7 ANTIBODIES, AND THEIR USES
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7386796B2 (ja) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022187511A1 (en) * 2021-03-03 2022-09-09 Veramorph Llc Dissociating polymer matrix compositions of fulvestrant and methods of their making and use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053752A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
EP0996628A2 (en) 1997-06-18 2000-05-03 ZymoGenetics Mammalian neuro-growth factor like protein
US20030166907A1 (en) 1997-06-18 2003-09-04 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20030166110A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974696B2 (en) 1997-10-17 2005-12-13 Genentech, Inc. PRO853 nucleic acids
US20030069178A1 (en) 1997-10-17 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US7105640B2 (en) 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US7195760B2 (en) 1997-10-17 2007-03-27 Genentech, Inc. Anti-pro363 antibodies
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US7202338B2 (en) 1998-03-31 2007-04-10 Genentech, Inc. PRO731 polypeptides
US7196176B2 (en) 1998-04-01 2007-03-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6962797B2 (en) 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
WO1999054437A2 (en) 1998-04-23 1999-10-28 Millennium Pharmaceuticals, Inc. Novel molecules of the t125-related protein family and uses thereof
US7067636B2 (en) 1998-05-06 2006-06-27 Genentech, Inc. Anti-pro 1017 antibodies
US20030186368A1 (en) 1998-05-13 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7019115B2 (en) 1998-05-22 2006-03-28 Genentech, Inc. Pro1017 polypeptides
US7220835B2 (en) 1998-07-30 2007-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030203446A1 (en) 1998-10-07 2003-10-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1135494A2 (en) 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004513602A (ja) 1999-03-08 2004-05-13 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2000063756A1 (en) 1999-04-16 2000-10-26 Fujikin Incorporated Parallel bypass type fluid feeding device, and method and device for controlling fluid variable type pressure system flow rate used for the device
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7214656B2 (en) 1999-04-28 2007-05-08 Genentech, Inc. PRO792 polypeptides
WO2001002563A2 (en) 1999-07-02 2001-01-11 Sagami Chemical Research Center HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
US20030119113A1 (en) 1999-07-20 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7442765B2 (en) 2000-08-24 2008-10-28 Genentech, Inc. Secreted transmembrane polypeptides and nucleic acids encoding the same
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030224984A1 (en) 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7135334B2 (en) 2001-06-20 2006-11-14 Genentech, Inc. PRO20044 nucleic acids
JP2006507813A (ja) 2002-10-04 2006-03-09 シエーリング アクチエンゲゼルシャフト 置換体活性化配列を有する修飾されたヘプシン分子及びその使用
DE602005018325D1 (de) 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
US20070160585A1 (en) 2004-03-30 2007-07-12 Kei Fujinaga Remedy for prion disease and method of producing the same
JP5599136B2 (ja) 2004-04-14 2014-10-01 ジェネンテック， インコーポレイテッド 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物
US20080292619A1 (en) 2004-08-03 2008-11-27 Mochida Pharmaceutical Co., Ltd. Pharmaceutical Composition Containing Meltrin Antagonist
PE20061401A1 (es) 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
CL2007003291A1 (es) * 2006-11-15 2008-07-04 Medarex Inc Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
RS53595B1 (sr) * 2007-07-16 2015-02-27 Genentech, Inc. Anti-cd79b antitela i imunokonjugati i metode upotrebe
ES2562790T3 (es) * 2007-07-17 2016-03-08 E. R. Squibb & Sons, L.L.C. Anticuerpos monoclonales contra Glipicano-3
PE20091029A1 (es) * 2007-09-26 2009-08-19 Genentech Inc Anticuerpos anti-alfa 5 beta 1
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES

Also Published As

Publication number Publication date
MX2011010570A (es) 2011-10-19
PE20120902A1 (es) 2012-08-08
TW201106970A (en) 2011-03-01
CN102459338A (zh) 2012-05-16
US20130129749A1 (en) 2013-05-23
US20130287779A1 (en) 2013-10-31
TWI428142B (zh) 2014-03-01
US8574576B2 (en) 2013-11-05
ECSP11011430A (es) 2011-12-30
UA105386C2 (uk) 2014-05-12
NZ595641A (en) 2013-07-26
JP2013055944A (ja) 2013-03-28
US20130129733A1 (en) 2013-05-23
WO2010129904A1 (en) 2010-11-11
CL2011002784A1 (es) 2012-08-31
CN103772500A (zh) 2014-05-07
CA2838400A1 (en) 2010-11-11
CA2760246A1 (en) 2010-11-11
JP2012525853A (ja) 2012-10-25
US20140051120A1 (en) 2014-02-20
SG175891A1 (en) 2011-12-29
CR20110576A (es) 2011-12-08
EP2427493A1 (en) 2012-03-14
MA33551B1 (fr) 2012-09-01
IL216115A0 (en) 2012-01-31
CO6450619A2 (es) 2012-05-31
JP5383905B2 (ja) 2014-01-08
AR076662A1 (es) 2011-06-29
US20100285009A1 (en) 2010-11-11
US20130149307A1 (en) 2013-06-13
ZA201207484B (en) 2013-06-26
RU2011149798A (ru) 2013-06-20
CN102875677A (zh) 2013-01-16
US20130324704A1 (en) 2013-12-05
KR20120005021A (ko) 2012-01-13
US20130064822A1 (en) 2013-03-14
AU2010245739B2 (en) 2013-07-11
TW201422237A (zh) 2014-06-16
US8404811B2 (en) 2013-03-26
AU2010245739A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
BRPI1007706A2 (pt) anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EP2770090A4 (en) METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY AND USES THEREOF AND KITS THEREFOR
BR112013024717A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
BR112015010817A2 (pt) anticorpos anti-hemaglutinina, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
UA115034C2 (uk) Імунокон'югат для застосування в лікуванні раку або запального порушення
CL2014001730A1 (es) Anticuerpo anti-epirregulina humanizado; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y agente terapeutico contra el cancer que lo comprende.
BR112013011819A2 (pt) ''método implantado por computador para comunicar estados mentais,produto de programa de computador incorporado em em meio legivel por computador para comunicar os estados mentais,sistema para compartilhar estados mentais e método por computador para compartilhar estados mentais''
MX385330B (es) Regulación transcripcional guiada por ácido ribonucleico.
BR112015002626A2 (pt) métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
HK1200837A1 (en) Compositions and methods for silencing aldehyde dehydrogenase
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
BR112013008480A2 (pt) anticorpos contra tumor e usos específicos dos mesmos
AR088514A1 (es) Inmunoligantes biespecificos dirigidos contra tnf
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
EA201591791A1 (ru) Антитела pac1 человека
HK1213946A1 (zh) 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
HK1201855A1 (en) Antibodies and methods of treating cancer
BR112016007402A2 (pt) anticorpos conjugados contra ly75 para o tratamento de câncer
CL2013002863A1 (es) Sistema y metodos de transaccion financiera.
BR112013030875A2 (pt) "anticorpos anti-cd52 humanizados, polinucleotídeo codificando os mesmos, vetor, célula hospedeira, composição compreendendo os mesmos, método para detecção da presença de antígeno de cd52 humana em uma amostra, bem como uso dos referidos anticorpos, polinucleotídeo e vetor"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2518 DE 09-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]